A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors.

Trial Profile

A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Letrozole (Primary) ; Tamoxifen
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BIG 1-98
  • Most Recent Events

    • 08 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 10 Apr 2017 Results (n=7963) assessing effect of cholesterol-lowering medication in combination with endocrine therapy on breast cancer outcomes, published in the Journal of Clinical Oncology.
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top